ArticleAntimicrobial agents and chemotherapy2010
OXA-134, a naturally occurring carbapenem-hydrolyzing class D beta-lactamase from Acinetobacter lwoffii.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance.International journal of molecular sciences · 2015Pooled it
- Genomic Characterization of Carbapenem-Resistant Bacteria from Beef Cattle Feedlots.Antibiotics (Basel, Switzerland) · 2023Article
- Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Phylogenomics ofFrontiers in microbiology · 2023Article
- Plasmids as Key Players inInternational journal of molecular sciences · 2022Review
- Carbapenemase Inhibitors: Updates on Developments in 2021.Journal of clinical medicine research · 2022Review
- Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals.Molecular biology reports · 2021Review
- Genome Analysis ofBiology · 2021Article
- Genomics ofMicrobial genomics · 2021Article
- Acquired Class D β-Lactamases.Antibiotics (Basel, Switzerland) · 2014Review
- OXA β-lactamases.Clinical microbiology reviews · 2014Review
- Identification of 50 class D β-lactamases and 65 Acinetobacter-derived cephalosporinases in Acinetobacter spp.Antimicrobial agents and chemotherapy · 2014Article
- OXA-235, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii.Antimicrobial agents and chemotherapy · 2013Article
- Biochemical and genetic characterization of carbapenem-hydrolyzing β-lactamase OXA-229 from Acinetobacter bereziniae.Antimicrobial agents and chemotherapy · 2012Article
- Genes encoding OXA-134-like enzymes are found in Acinetobacter lwoffii and A. schindleri and can be used for identification.Journal of clinical microbiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter lwoffii, a species whose natural habitat is the human skin, intrinsically possesses a chromosomal gene encoding a carbapenem-hydrolyzing class D β-lactamase, OXA-134. This species may therefore constitute a reservoir for carbapenemase genes that may spread among other Acinetobacter species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.